- FIBROSIS REGRESSION CONFERS LONGTERM CLINICAL BENEFITS IN PATIENTS ON ANTI- HBV THERAPY: AN EXTENSION ASSESSMENT BY P- I- R SCORESun, Yameng; Chen, Wei; Chen, Shuyan; Wu, Xiaoning; Zhang, Xinxin; Zhang, Lingyi; Zhao, Hong; Xu, Mingyi; Chen, Yongpeng; Piao, Hongxin; Li, Ping; Li, Lei; Jiang, Wei; Li, Xiaodong; Xing, Huichun; Liu, Xudong; Zhang, Yuxi; Wang, Bingqiong; Zhou, Jialing; Meng, Tongtong; Zhao, Xinyan; Shao, Chen; Kong, Yuanyuan; Zhao, Xinyu; Ou, Xiaojuan; Liu, Chenghai; Jia, Jidong; You, HongMeeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, 2023-11-10 To 2023-11-14.
- Editorial: the three tenors in HBV-TDF, TAF and now TMF. Authors' replyLiu, Zhihong; Liu, Ziyang; Xiao, Ling; Niu, Junqi; Hou, Jinlin*Alimentary Pharmacology and Therapeutics, 2022, 55(1): 121-121.
- A RANDOMISED, DOUBLE - BLIND, PHASE 3, NON-INFERIORITY TRIAL OF PRADEFOVIR MESYLATE VERSUS TENOFOVIR DISOPROXIL FUMARATE FOR PAITENTS WITH CHRONIC HEPATITIS B VIRUS INFECTIONGao, Yanhang; Wang, Zhongfeng; Wang, Xinrui; Kong, Fei; Wu, Guicheng; Zhang, Guoqiang; Li, Guang-Ming; Yao, Lvfeng; Liu, Weidong; Shang, Jia; Yu, Yunsong; Zhao, Weifeng; Hou, Jinlin; Dang, Shuangsuo; Yuan, Shufen; Hu, Guoxin; Zhong, Bei; Chen, Hui; Chen, Suling; Dong, Xiaoping; Xie, Xiangping; Liu, Zhenguo; Zhang, Zong; Song, Xinwen; Mao, Qing; Jiang, Yongfang; Meng, Chenxin; Yuan, Zhaoxu; Su, Zhijun; Mao, Qianguo; Bai, Yichun; Yu, Lei; Tan, Youwen; Fan, Huizhen; Jiao, Zhiyong; Fu, XihuaMeeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, 2023-11-10 To 2023-11-14.
会议论文
LONGER-TERM EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) IN HBV-INFECTED PATIENTS; CHANGES IN EGFR, FIB4, ALT, AND DNA SUPPRESSION
18阅读
